Leif Bertilsson

Prof. Dr. Leif Bertilsson


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2008 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
KKKp Kanebratt
Kp Kanebratt
UDUlf Diczfalusy
Ulf Diczfalusy
TBT Bäckström
T Bäckström
ESE Sparve
E Sparve
EBE Bredberg
E Bredberg
LBLeif Bertilsson
Leif Bertilsson

26 September 2007 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
LBLeif Bertilsson
Leif Bertilsson

Verified
Journal Article
Open access
PDF file
XLXueqing Li
Xueqing Li
RTRoslyn Thelingwani
Roslyn Thelingwani
LBLeif Bertilsson
Leif Bertilsson
UDUlf Diczfalusy
Ulf Diczfalusy
TATommy B. Andersson
Tommy B. Andersson
CMCollen Masimirembwa
Collen Masimirembwa
In this study, we aimed to evaluate the utility of endogenous 1β-hydroxy-deoxycholic acid/total deoxycholic acid ratio (1β-OH-DCA/ToDCA) in spot urine as a surrogate marker of cytochrome P450 3A (CYP3A) activity in the assessment inhibition-based drug–drug interactions in healthy volunteers. This was accomplished through an open-label, three-treatment parallel-arm study in healthy male volunteers from Zimbabwe. Each group received itraconazole (ITZ; 100 mg once daily; n = 10), fluconazole (FKZ; 50 mg once daily; n = 9), or alprazolam (APZ; 1 mg once daily; n = 8) orally. Midazolam (MDZ), dosed orally and intravenously, was used as a comparator to validate the exploratory measures of CYP3A activity and the effects of known inhibitors. Urinary metabolic ratios of 1β-OH-DCA/ToDCA before and after CYP3A inhibitor treatment showed a similar magnitude of inhibitory effects of the three treatments as that measured by oral MDZ clearance. The maximum inhibition effect of a 75% reduction in the 1β-OH-DCA/ToDCA ratio compared to the baseline was achieved in the ITZ group following six once-daily doses of 100 mg. The correlations of the two markers for CYP3A inhibitor treatment were significant (rs = 0.53, p < 0.01). The half-life of urinary endogenous 1β-OH-DCA/ToDCA was estimated as four days. These results suggested that 1β-OH-DCA/ToDCA in spot urine is a promising convenient, non-invasive, sensitive, and relatively quickly responsive endogenous biomarker that can be used for CYP3A inhibition-based drug–drug interaction in clinical studies.


1 November 2010 in Pediatric Research
Verified
Journal Article
Closed access
PDF file
KWK Wide
K Wide
SES Ekmark-Sergel
S Ekmark-Sergel
HNH Nylen
H Nylen
UDU Diczfalusy
U Diczfalusy
LBLeif Bertilsson
Leif Bertilsson